Updates in Metastatic Colorectal Cancer

Colorectal cancer is a heterogeneous disease, with tumor location and microsatellite instability status influencing patient outcomes. Complicating treatment decisions is the presence of liver metastases, which present both an obstacle and an opportunity, as they can hinder the effectiveness of immunotherapy but may be addressed by both existing and emerging therapies. Agents targeting BRAF and HER2 aberrations as well as biomarkers, such as circulating tumor DNA and DPD, offer potential for more personalized approaches to treatment. The current NCCN Guidelines provide evidence-based recommendations for the management of colorectal cancer and reflect ongoing developments in the therapeutic landscape.